Other equities research analysts also recently issued research reports about the company. Deutsche Bank AG reiterated a buy rating and set a $31.00 price objective on shares of Endo International PLC in a research report on Wednesday, June 15th. JMP Securities reiterated a buy rating on shares of Endo International PLC in a research report on Wednesday, June 29th. Vetr downgraded Endo International PLC from a strong-buy rating to a buy rating and set a $19.14 price objective for the company. in a research report on Thursday, July 7th. JPMorgan Chase & Co. set a $40.00 price objective on Endo International PLC and gave the company a buy rating in a research report on Tuesday, August 9th. Finally, Citigroup Inc. cut their target price on shares of Endo International PLC from $40.00 to $25.00 and set a buy rating on the stock in a research note on Friday, September 16th. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and eleven have issued a buy rating to the company. The company has a consensus rating of Hold and a consensus target price of $39.32.
Endo International PLC (NASDAQ:ENDP) traded down 0.172% during trading on Thursday, reaching $20.894. The company’s stock had a trading volume of 3,012,059 shares. The firm has a 50-day moving average price of $21.48 and a 200-day moving average price of $21.28. Endo International PLC has a 52 week low of $12.56 and a 52 week high of $72.85. The firm’s market capitalization is $4.65 billion.
Endo International PLC (NASDAQ:ENDP) last announced its quarterly earnings data on Monday, August 8th. The company reported $0.86 EPS for the quarter, beating analysts’ consensus estimates of $0.74 by $0.12. Endo International PLC had a positive return on equity of 15.54% and a negative net margin of 25.90%. The company earned $921 million during the quarter, compared to the consensus estimate of $873.50 million. During the same quarter in the prior year, the firm earned $1.08 EPS. The company’s quarterly revenue was up 25.3% compared to the same quarter last year. On average, equities analysts anticipate that Endo International PLC will post $4.56 EPS for the current fiscal year.
Large investors have recently added to or reduced their stakes in the stock. Meeder Asset Management Inc. bought a new stake in Endo International PLC during the first quarter valued at $139,000. LS Investment Advisors LLC boosted its stake in Endo International PLC by 152.3% in the second quarter. LS Investment Advisors LLC now owns 13,661 shares of the company’s stock valued at $213,000 after buying an additional 8,247 shares during the last quarter. Icon Advisers Inc. Co. bought a new stake in Endo International PLC during the second quarter valued at $218,000. IFP Advisors Inc boosted its stake in Endo International PLC by 103,542.9% in the second quarter. IFP Advisors Inc now owns 14,510 shares of the company’s stock valued at $226,000 after buying an additional 14,496 shares during the last quarter. Finally, Canada Pension Plan Investment Board boosted its stake in Endo International PLC by 33.0% in the first quarter. Canada Pension Plan Investment Board now owns 9,019 shares of the company’s stock valued at $254,000 after buying an additional 2,237 shares during the last quarter. Institutional investors and hedge funds own 96.64% of the company’s stock.
About Endo International PLC
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.